Table 4 Characteristics of liquid biopsy samples
Variable | At diagnosis (%) n = 44 | After treatment initiation (%) n = 51 | Total samples (%) n = 95 |
|---|---|---|---|
CA19-9 (n = 90) | |||
> 4515 U/mL | 22 (51.2%) | 9 (19.1%) | 34.4 (33.3%) |
< 4515 U/mL | 21 (48.8%) | 38 (80.9%) | 65.6 (66.7%) |
cfDNA concentration | |||
> 31.8 ng/mL | 22 (50%) | 20 (39.2%) | 42 (44.2%) |
< 31.8 ng/mL | 22 (50%) | 31 (60.8%) | 53 (55.8%) |
RAS status in plasma | |||
RAS mutated | 35 (79.5%) | 15 (29.4%) | 50 (52.6%) |
RAS wild-type | 9 (20.5%) | 36 (70.6%) | 45 (47.4%) |
MAF | |||
> 2.01% | 22 (50%) | 2 (3.9%) | 24 (25.3%) |
< 2.01% | 22 (50%) | 49 (96.1%) | 71 (74.7%) |
NPTX2 | |||
Methylated | 35 (79.5%) | 42 (82.4%) | 77 (81.1%) |
Unmethylated | 9 (20.5%) | 9 (17.6%) | 18 (18.9%) |
NPTX2 methylation | |||
> 6.06% | 26 (59.1%) | 23 (45.1%) | 49 (51.6%) |
< 6.06% | 18 (40.9%) | 28 (54.9%) | 46 (48.4%) |